Sugi Predict

Sugi Predict / Compounds / SCHEMBL2653607

SCHEMBL2653607

SCHEMBL2653607

CCSc1ccc(Br)cn1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GBA1 P04062 1/20 0.46
▸ CHRNB2 P17787 1/20 0.42
▸ CHRNA4 P43681 1/20 0.42
▸ PIK3CD O00329 1/20 0.40
▸ PIK3CA P42336 1/20 0.40
▸ PIK3CB P42338 1/20 0.40
▸ PI4KA P42356 1/20 0.40
▸ PIK3CG P48736 1/20 0.40
▸ PI4KB Q9UBF8 1/20 0.40
▸ RAB9A P51151 7/20 0.37
▸ NPC1 O15118 6/20 0.37
▸ SMN1; SMN2 Q16637 5/20 0.37
▸ NFKB1 P19838 2/20 0.37
▸ NFKB2 Q00653 2/20 0.37
▸ RELA Q04206 2/20 0.37
▸ LMNA P02545 1/20 0.37
▸ KDM4E B2RXH2 4/20 0.37
▸ ALDH1A1 P00352 4/20 0.37
▸ MAPT P10636 3/20 0.37
▸ PKM P14618 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15633020 0.81 RAB9A (0.42) GBA1RAB9ANPC1SMN1; SMN2NFKB1
SCHEMBL2174245 0.77 CHRNB2 (0.43) CHRNB2CHRNA4PIK3CDPIK3CAPIK3CB
SCHEMBL12659908 0.77 NPC1 (0.50) CHRNB2CHRNA4PIK3CDPIK3CAPIK3CB
SCHEMBL13173479 0.76 HRH1 (0.38) GBA1LMNAKDM4EALDH1A1PKM
SCHEMBL211656 0.76 — —
SCHEMBL1492564 0.75 PIK3CD (0.47) CHRNB2CHRNA4PIK3CDPIK3CAPIK3CB
SCHEMBL850711 0.75 CHRNB2 (0.42) CHRNB2CHRNA4PIK3CDPIK3CAPIK3CB
SCHEMBL2348177 0.75 KDM4E (0.42) CHRNB2CHRNA4PIK3CDPIK3CAPIK3CB
SCHEMBL9330826 0.75 CHRNB2 (0.42) CHRNB2CHRNA4PIK3CDPIK3CAPIK3CB
SCHEMBL11731794 0.75 ALDH1A1 (0.45) GBA1RAB9ANPC1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4134364-B1 BROMODOMAIN INHIBITORS CELGENE QUANTICEL RES INC (US) 2025-07-30 — — EP disclosed
US-11884680-B2 Bromodomain inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2024-01-30 — — US disclosed
EP-4134364-A2 BROMODOMAIN INHIBITORS Celgene Quanticel Research, Inc. (US) 2023-02-15 — — EP disclosed
EP-4134364-A2 BROMODOMAIN INHIBITORS Celgene Quanticel Research, Inc. (US) 2023-02-15 — — EP disclosed
US-20220315601-A1 BROMODOMAIN INHIBITORS CELGENE QUANTICEL RESEARCH, INC. (US) 2022-10-06 — — US disclosed
EP-3640241-B1 BROMODOMAIN INHIBITORS CELGENE QUANTICEL RES INC (US) 2022-09-28 — — EP disclosed
CN-108558889-B Bromodomain inhibitors 赛尔基因昆蒂赛尔研究公司 2021-11-05 — — CN disclosed
US-10941160-B2 Bromodomain inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2021-03-09 — — US disclosed
US-10941160-B2 Bromodomain inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2021-03-09 — — US disclosed
US-20200148703-A1 BROMODOMAIN INHIBITORS CELGENE QUANTICEL RESEARCH, INC. (US) 2020-05-14 — — US disclosed
US-20080188502-A1 New Compounds I ASTRAZENECA AB (SE) 2008-08-07 — — US disclosed
WO-2008002244-A2 IMIDAZOL-PYRIMIDINE DERIVATIVES FOR TREATMENT OF DISEASES RELATED TO GLYCOGEN SYNTHASE KINASE (GSK3) ASTRAZENECA AB (SE) 2008-01-03 — — WO disclosed
WO-2008002244-A2 IMIDAZOL-PYRIMIDINE DERIVATIVES FOR TREATMENT OF DISEASES RELATED TO GLYCOGEN SYNTHASE KINASE (GSK3) ASTRAZENECA AB (SE) 2008-01-03 — — WO disclosed
US-7262196-B2 Tri(cyclo) substituted amide glucokinase activator compounds PROSIDION LIMITED (GB) 2007-08-28 — — US disclosed
EP-1594863-A1 TRI(CYCLO) SUBSTITUTED AMIDE GLUCOKINASE ACTIVATOR COMPOUNDS Prosidion Limited (GB) 2005-11-16 — — EP disclosed
US-20040186290-A1 Tri(cyclo) substituted amide glucokinase activator compounds OSI PHARMACEUTICALS, INC. 2004-09-23 — — US disclosed
WO-2004072066-A1 TRI(CYCLO) SUBSTITUTED AMIDE GLUCOKINASE ACTIVATOR COMPOUNDS PROSIDION LIMITED (GB) 2004-08-26 — — WO disclosed
EP-0350804-B1 Process for the preparation of halosilanes HOECHST AG (DE) 1994-04-20 — — EP disclosed
US-5028706-A Process for the preparation of halosilanes HOECHST AKTIENGESELLSCHAFT (DE) 1991-07-02 — — US disclosed
EP-0350804-A2 Process for the preparation of halosilanes HOECHST AKTIENGESELLSCHAFT (DE) 1990-01-17 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220315601-A1 BROMODOMAIN INHIBITORS BRD3, EP300, BRPF3 GBA1 3605/4885CHRNB2 3009/4885CHRNA4 3170/4885
US-20080188502-A1 New Compounds I SLC10A1, REN, SLC5A1 GBA1 71/4885CHRNB2 4401/4885CHRNA4 3955/4885
US-10941160-B2 Bromodomain inhibitors BRD3, EP300, BRPF3 GBA1 3605/4885CHRNB2 3009/4885CHRNA4 3170/4885
US-20200148703-A1 BROMODOMAIN INHIBITORS BRD3, EP300, BRPF3 GBA1 3605/4885CHRNB2 3009/4885CHRNA4 3170/4885
US-20040186290-A1 Tri(cyclo) substituted amide glucokinase activator compounds GCKR, GCK, GALK1 GBA1 308/4885CHRNB2 3914/4885CHRNA4 3590/4885
US-11884680-B2 Bromodomain inhibitors BRD3, EP300, BRPF3 GBA1 3605/4885CHRNB2 3009/4885CHRNA4 3170/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.